Imetelstat in Geron trials maybe working

The stock should be moving upward on the comments from the latest conference call regarding Imetelstat.

The trials for Imetelstat are looking at Progression-free survival. They are looking at how long people are going free of new or progressing disease.

With that said the company has targets when they think they will see lung CA patients or breast CA patients disease progress. If they are meeting these target dates the results should be released when they are expected (such as Imetelstat in the lung cancer patients). However if the cancer is being held at bay there is lengthening of the progression free survival and such the data or events will cause a delay in data results such as with the breast cancer trial. [MAYBE]

All in all this trial looks to meet or beat its end points based on progression free survival and keeping data release dates on target or delaying them.

This was from Yahoo's message broad on Geron. I agree with the statement that the delay in reporting results MAYBE due the lengthening of the progression free survival of said patients. This would make Geron a $5-10 dollar, maybe more if the other Phase two trial resuults are good. Then Geron should have no problem finding a partner. With a partner we could hit $20 and with euphoria hitting the stock a run to $40 is possible. Again this can only happen if the results are good.

Good luck in this rigged casino,